Extra-financing to increase visibility
Extra-financing to increase visibilityFINANCING ISSUE
FACT
Crossject announced it has issued zero-coupon convertible bonds (€5.7m) at 92% of their nominal value, maturing on 31 December 2021, convertible at the lowest price between €2.30 and an average market price less 10%. Gemmes Venture (Crossject’s main shareholder) has invested €2.1m in this issue, in line with its shareholding.
ANALYSIS
If the timing came a bit as a surprise, although forecasting it is impossible, the move is not. After the €2.6m structured financing agreed upon last month (see our Latest dated 19 November), this new issue will enable the group to finance the year to come. In short, and after the exercise of options (€3.2m), the group has raised c. €11.5m to which should be added public incentives (PIAVE, tax credit…) leading to a total of €13.4m to finance the company. In October, management had estimated Crossject would need c.€12m to finance its development over the next twelve months, so the issue is perfectly in line with expectations in terms of size. Obviously, there could/will be a dilutive impact once the bonds are converted. At today’s price (€1.91 on Friday), this would lead to the creation of 3.68m shares (i.e. 18.5% of the total 19.72m diluted shares). All in all, we consider the issue as positive insofar as it secures the group’s need for the year to come, which should see the first market approvals. That said, the implied dilution will take its toll on our valuation, despite the cash inflow. We will adjust our numbers, considering that the conversion will take place at €2.3 (which implies that the share price will have gone up between now and the day of conversion), reducing the dilution to some 13.5%.
IMPACT
We will adjust our numbers, considering that the bonds will be converted at some stage during FY20. The current price is penalising, and it is likely that a real conversion will in fact take place at a higher price than today’s, thus our choice to use the €2.3 as the conversion price in FY20.
Crossject SA is a France-based company that designs and develops medical injection systems. The Company specializes in needle-free, pre-filled, single-use injection systems for intradermal, subcutaneous and intramuscular applications for pharmaceutical companies. Is also has a pipeline and three drugs in the preclinical or clinical phase of research. The Company's products, which are based on well-known injectable drugs (chemicals and biologics), are designed to enhance patients' safety, compliance and comfort. Crossject's first ZENEO SUPERGENERIC product is expected to reach the market in the year 2015. The Company has industrial partnerships with Hirtenberger and Recipharm.
AlphaValue Corporate Services capitalise on the research and credit analysis expertise deployed by AlphaValue with major institutional investors at European level over the past nine years. The proprietary tools and processes enabling AlphaValue Corporate Services to establish a valuation and/or a credit risk assessment are identical to those used by AlphaValue to the benefit of its institutional clients. The only difference is the recognition that a company evaluation cannot be dissociated from the fact that the latter is paying for the service (AlphaValue Corporate Services), as opposed to the investor footing the bill (AlphaValue). AlphaValue’s research tools are characterised by the transparency of the valuation methodologies, their responsiveness to market data and by nine years’ experience of a universe numbering more than 450 European companies. Through its coverage and sector exhaustiveness, AlphaValue ranks alongside the major research houses in Europe and constitutes the only new entrant to the European space in the past decade. This significant presence is reflected in an unrivalled distribution capability via platforms commonly adopted by investors to access research: Factset, Bloomberg, Capital IQ and the numerous websites. AlphaValue is one the largest research contributors to these platforms, to the benefit of AlphaValue Corporate Services issuer clients. The AlphaValue Corporate Services analysts are AlphaValue’s sector specialists. Their robust knowledge of the business models in their sectors enables the rapid generation of incisive, relevant research and advantageous interaction with the management teams.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.